by Anis Fahandej-Sadi | Dec 5, 2024
If you’re reading this, you’re probably aware of the massive strides the cell and gene therapy (CGT) industry has made in the last few years. Between 2017 and 2022, six CGT products were approved by the U.S. Food and Drug Administration, but we saw eight approvals in...
by Stacey Johnson | Nov 29, 2024
Are you familiar with the Gartner Hype Cycle? It’s a way of separating reality from hype when it comes to emerging technologies – like cell and gene therapies (CGTs). The hype cycle employs a graph to present the maturity of new technologies as they pass through five...
by Lyla El-Fayomi | Nov 14, 2024
I’ve once again divided up the October edition of RMNU🔬 by trending research topic. Read on for remarkable placental science, new research involving in vivo genetic engineering, and more! Trend of the month: Healing via placenta Millions of placentas are discarded...
by Stacey Johnson | Oct 25, 2024
Michel Sadelain is the 2024 Gairdner International Award laureate, along with Dr. Zelig Eshhar, for his “seminal contributions to the conception, development and application of CD19-CAR T cell therapy for cancer.” It’s been a good year for Dr. Sadelain, who also won...
by Lyla El-Fayomi | Oct 10, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. Fall is finally here! September really delivered – lots of interesting...
by Laya Kiani | Sep 26, 2024
The regenerative medicine (RM) market is highly competitive, with major biopharmaceutical companies and innovative startups vying for dominance. As companies seek regulatory approval and work to establish their presence in this fast-evolving industry, the competitive...
Comments